Document is current
Any future updates will be listed below
-
Authors
Mandino, Francesca https://orcid.org/0000-0002-5605-0854
Shen, Xilin
Desrosiers-Grégoire, Gabriel https://orcid.org/0000-0003-2197-1183
O’Connor, David https://orcid.org/0000-0002-8885-518X
Mukherjee, Bandhan
Owens, Ashley
Qu, An
Onofrey, John
Papademetris, Xenophon
Chakravarty, M. Mallar https://orcid.org/0000-0002-0759-5508
Strittmatter, Stephen M. https://orcid.org/0000-0001-8188-3092
Lake, Evelyn M. R. https://orcid.org/0000-0001-8255-8013
- License Information
-
More Information
Article History
Received: 11 March 2024
Revised: 26 September 2024
Accepted: 30 September 2024
First Online: 18 October 2024
Competing interests
: SMS is a Founder, Consultant, Equity Holder and Director of Allyx Therapeutics seeking to develop mGluR5-directed therapies for Alzheimer’s and Parkinson’s Disease. XP is a consultant for the Brain Electrophysiology Laboratory Company. XP also consults and has an ownership stake in Veridat.
: All procedures were approved by the Yale Institutional Animal Care and Use Committee (IACUC; IACUC #2023-20284; 2023-07281) and followed the National Institute of Health Guide for the Care and Use of Laboratory Animals. Human analyses were carried out via data from the publicly available NeuroSynth platform.
